Dr. Masakazu Toi
Kyoto University, Japan

Email: [email protected]

Qualifications

2007 Professor, Kyoto University, Japan

2003-Present Professor, Science University of Tokyo, Japan

2003 Guest Professor, Hong Kong University, Japan

Publications (Selected)

1. Burstein, H. J., et al. "Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021." Annals of oncology 32.10 (2021): 1216-1235.
2. Glaviano, Antonino, et al. "Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment." Drug Resistance Updates 76 (2024): 101103.
3. Takada, Masahiro, and Masakazu Toi. "Neoadjuvant treatment for HER2-positive breast cancer." Chinese clinical oncology 9.3 (2020): 32-32.
4. Turner, Nicholas C., et al. "Capivasertib in hormone receptor–positive advanced breast cancer." New England Journal of Medicine 388.22 (2023): 2058-2070.
5. Johnston, Stephen RD, et al. "Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial." The lancet oncology 24.1 (2023): 77-90.
6. Sledge Jr, George W., et al. "The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial." JAMA oncology 6.1 (2020): 116-124.
7. Johnston, Stephen RD, et al. "Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE)." Journal of Clinical Oncology 38.34 (2020): 3987-3998.
8. Tolaney, Sara M., et al. "Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer." New England Journal of Medicine (2025).
9. Bradley, Rosie, et al. "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials." The Lancet Oncology 22.8 (2021): 1139-1150.
10. Loibl, Sibylle, et al. "Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the Penelope-B trial." Journal of clinical oncology 39.14 (2021): 1518-1530.
11. Piccart, Martine, et al. "Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up." Journal of Clinical Oncology 39.13 (2021): 1448-1457.
12. Bradley, Rosie, et al. "Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials." The Lancet Oncology 23.3 (2022): 382-392.
13. Taylor, Carolyn, et al. "Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials." The Lancet 402.10416 (2023): 1991-2003.
14. Punyawatthananukool, Siwakorn, et al. "Prostaglandin E2-EP2/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells." Nature Communications 15.1 (2024): 9464.
15. Costa, Luis, et al. "Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers." The Breast 73 (2024): 103623.

Profile Details
https://www.ccii.med.kyoto-u.ac.jp/en/research/divisions-labs/professor-masakazu-toi/
https://breastcancerinyoungwomen.org/masakazu-toi-md-phd/
https://apbcs.org/masakazu-toi/

WoS Researcher ID:  AFO-8377-2022